Skip to main content

ARKG Leads in 1-Week Returns as Biotech Rebounds

Biotech funds began their rebound last week as positive trial data and merger and acquisition news revived the sector. The ARK Genomic Revolution ETF (ARKG) rallied 7.15% over one week, ahead of all other ETFs in the health and biotech equities ETFs category, according to VettaFi. The actively...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.